Robert D Ladner, PhD
Chief Executive Officer & Founder
Dr. Robert Ladner is Founder and Chief Executive Officer of CV6 Therapeutics and a leading translational cancer scientist with more than three decades of experience in oncology research and drug development.
His work has focused on nucleotide metabolism, DNA repair, and mechanisms of resistance to chemotherapy, particularly in relation to 5-fluorouracil (5-FU). He was among the first to elucidate the role of uracil-DNA misincorporation in chemotherapy resistance, laying the groundwork for a new class of targeted cancer therapeutics. His discoveries established a critical link between dUTPase overexpression and clinical resistance to 5-FU in colorectal cancer.
Dr. Ladner previously served on the faculty at the University of Southern California (USC) Norris Comprehensive Cancer Center, where his research advanced the understanding of chemotherapy resistance and informed the development of novel therapeutic strategies. In 2015, he was appointed Reader in the School of Medicine, Dentistry and Biomedical Sciences at Queen’s University Belfast, where he continues to advance research in cancer therapeutics.
He founded CV6 Therapeutics to develop first-in-class therapies designed to enhance the effectiveness of cornerstone treatments in cancer, with additional applications in inflammatory disease.
He sits on the Board of Directors of CV6 Therapeutics, Inc. and CV6 Therapeutics (NI) Ltd.